Uterine sarcomas are rare subtypes of primary urogenital tumours and need tailored treatment. This study aimed to examine the impact of diagnosis and treatment on health-related quality of life (HRQoL) in patients with uterine sarcoma and measures available to assess HRQoL in this group.
Thirteen patients with uterine sarcoma and 23 health care professionals were purposively sampled from sarcoma reference centers and participated in a semi-structured interview exploring HRQoL. Patients were also asked to review the EORTC QLQ-C30 and EORTC QLQ-EN24 for relevance. Data were analysed using thematic analysis and descriptive statistics.
The most commonly reported physical health issues were related to sexual dysfunction and urological symptoms. Hormone-related issues and gastrointestinal symptoms were also identified. Cancer-generic issues such as functional problems, fatigue, pain, and treatment-related adverse effects were also reported. Regarding mental health, fears (about having sex, of recurrence, or of death), altered body-image, and dealing with lacking knowledge regarding sarcoma had an impact on HRQoL. Social health issues were related to the impact on relationships with others, limitations in undertaking activities, loss of independence, changes in work or study capacity, and financial difficulties. Most of the items of the EORTC QLQ-C30 and EORTC QLQ-EN24 questionnaires were rated as relevant. Questions about lack of knowledge about sarcoma, shock of diagnosis, and menopausal symptoms were lacking from existing measures.
Uterine sarcoma patients experience a variety of concerns covering the physical, mental, and social domains of HRQoL that are in the main EORTC instruments, but not all of them. Combining cancer-generic, location- and sarcoma-specific items is recommended to assess HRQoL in this patient group.
Trial registration NCT04071704.
Being diagnosed with and treated for sarcoma has a significant impact on health-related quality of life (HRQoL) [1, 2]. However, few studies have investigated HRQoL outcomes in patients with uterine soft tissue sarcoma (uterine STS) specifically. Assessment of HRQoL in this rare subgroup of sarcomas is difficult because tailored instruments for HRQoL measurement are currently not available. Exploration of the HRQoL issues that patients with uterine STS experience and assessing content validity of existing patient-reported outcome measures (PROMs) will help increase knowledge of HRQoL outcomes in this patient group.
STS account for only a small proportion of primary urogenital tumours, i.e. 3% of all uterine malignancies. Data on urogenital sarcomas as a group are hardly available and limited survival rates are reported for these rare sarcoma locations, with the exception of uterine sarcoma. In this group, survival greatly varies depending on histological subtypes with uterine leiomyosarcoma that has a 5-year relative survival across all stages of 42%, compared to 72% for endometrial stromal tumours .
Tailored treatment is very important in STS and differs from treatment for endometrial cancer, which occurs at the same anatomical location. The cornerstone of treatment for localized uterine STS is en bloc total hysterectomy. A survival benefit of bilateral salpingo-oophorectomy has not been demonstrated especially not in pre-menopausal women. Routine lymph node dissection is not indicated . Adjuvant chemotherapy or radiation therapy have not been proven to increase survival rates, but may be considered in selected cases [5, 6]. Adjuvant hormonal therapy might be considered in patients with low grade, estrogen/progesterone receptor positive endometrial stromal sarcomas . In metastatic uterine sarcoma, doxorubicin remains standard first line treatment. However, first-line combination chemotherapy with gemcitabine and docetaxel can be considered as well in advanced uterine leiomyosarcoma patients . In selected cases of metastatic hormone receptor positive ESS and uterine leiomyosarcomas, hormonal therapy is an option [7, 9].
In addition to objective treatment outcomes, such as survival rates, subjective patient-reported outcomes (PROs) including health-related quality of life (HRQoL) can be used to assess treatment effectiveness. HRQoL is a multidimensional concept that includes the patient’s perception of the impact of the disease and its treatment on physical/biological (including symptoms), psychological and social functioning, according to the biopsychosocial model [10, 11].
An instrument to measure HRQoL in uterine STS patients during and after treatment does currently not exist, although some symptoms were included in a non-validated sarcoma-specific symptom-inventory . The EORTC Quality of Life Core Questionnaire 30 (EORTC QLQ-C30)  combined with the EORTC QLQ-Endometrial Cancer Module (EORTC QLQ-EN24)  are validated to assess HRQoL in women treated for endometrial cancer, however it is unknown if this measurement strategy is applicable for the uterine STS population.
One cohort study has previously investigated HRQoL, using the EORTC Quality of Life Core Questionnaire 30 (EORTC QLQ-C30), and long-term treatment effects in a heterogeneous group of bone and soft tissue sarcoma survivors. Fifteen female urogenital sarcoma survivors were included, with over 40% reporting pain in the back, urge incontinence, flatulence, abdominal cramps, bloated feeling of the abdomen, and complaints similar to menopause . Two studies have investigated patient-reported symptoms at time of diagnosis of uterine sarcoma, being heavy menstrual flow, painful menstruation, “persistent abdominal pain that is getting worse” and “fibroids or lumps that are increasing in size” [12, 16]. Nevertheless, information about the psychosocial impact of the disease and treatment is lacking.
The current mixed-method study aimed to gain more insight in the HRQoL issues that patients with uterine STS face and how this impact can be measured, to improve sensitive HRQoL assessment in research and to further optimize personalized care in this rare cancer type.
This inductive analysis is part of a larger mixed method study with a convergent design to determine a strategy for HRQoL measurement in all types of adult sarcomas  (clinicaltrials.gov NCT04071704), conducted in multiple countries in Europe and beyond. Outside Europe, patients were recruited from Australia, Canada, Hong Kong, India, Israel, Jordan, and the United States. The qualitative approach was chosen to perform a phenomenological inquiry of HRQoL issues experienced by uterine sarcoma patients. Subsequently, the quantitative approach was used to assess whether existing questionnaires for patients with cancer at the same anatomical location (i.e. endometrial cancer) can be used to assess HRQoL in this patient group rather than creating a completely new item list.
Sample and procedure
Inclusion and exclusion criteria and procedure for recruitment for this study have been described elsewhere . Recruitment continued until saturation was reached for the sarcoma population as a whole in the larger study. A stratification matrix was used to ensure that the heterogeneity of the sarcoma population in terms of tumour location, histological subtypes, disease stage (localized, metastatic disease/ local relapse), treatments, age, sex, and physical impairments was adequately covered. At least 12 patients per location were recruited. For this analysis, patients with primary sarcoma in the uterus were selected.
Furthermore, international sarcoma specialists were invited and interviewed by the study coordinator or the local principal investigator. The sarcoma specialists worked as medical oncologists, radiation therapists, surgeons, nurse specialists, rehabilitation physicians, psychologists, or social workers and are hereafter referred to as health care professionals (HCPs). For this analysis, only HCPs who had experience with uterine STS patients were selected.
All patients gave written informed consent prior to the interview. Sociodemographic data were collected from the medical file or obtained from the patient directly at study entry. Clinical data was also collected from the medical file by a member of the study team.
Ethical approval was given by the Institutional Review Board of the Netherlands Cancer Institute (IRB18121). In the other international participating centres, this study was approved by their ethical committees according to local regulations.
Semi-structured interviews were conducted between July 2019 and July 2020, by a trained physician, psychologist, researcher, or research nurse (DdH, EL, SSi, SSo, SSa, MF, VB), using an interview guide. Participants were asked an open-ended question about their cancer history and experience and were then prompted according to the interview guide provided to all collaborators (Additional file 1: File 1). Subsequently, the participant was asked to review (i.e. not complete) the EORTC QLQ-C30 and EORTC QLQ-EN24, and comment on topic and item relevance with regard to the period from diagnosis up to time of this study (scored as 1—“not all relevant”, 2—“a little relevant”, 3—“quite a bit relevant” and 4—“very much relevant”).
The participant was encouraged to “think aloud”, to provide feedback on the reasons for his/her ratings. Finally, the participants were asked whether items could be deleted or other HRQoL issues that they believe to be important could be added to the questionnaires. Given the large sample size and heterogeneity of the population in the large mixed method study, member checking was not done. Reflexivity was only addressed through the interpretations by the different international interviewers speaking with sarcoma patients and HCPs.
The EORTC QLQ-C30 version 3.0 was developed to measure HRQoL in patients with cancer . This 30-item questionnaire consists of five functional scales (physical, role, cognitive, emotional and social), a global quality of life scale, three symptom scales (fatigue, pain, nausea and vomiting) and single items assessing common symptoms (dyspnoea, loss of appetite, sleep disturbance, constipation, and diarrhoea) and perceived financial impact of the disease. Cronbach’s alpha coefficients range from 0.52 to 0.89 after treatment (physical functioning 0.71, role functioning 0.52, cognitive functioning 0.73, emotional functioning 0.80, social functioning 0.77, global QoL 0.89, fatigue 0.85, nausea and vomiting 0.73, pain 0.76). Scaling successes were noted in 96% and al inter-scale correlations were statistically significant.
The EORTC QLQ-EN24 was developed for HRQoL measurement in patients with endometrial cancer and consists of 24 items . It measures five symptom scales (lymphedema, urological symptoms, gastrointestinal symptoms, poor body image and sexual/vaginal problems), five single symptoms items (pain in back and pelvis, tingling/numbness, muscular pain, hair loss and taste change) and three functional single items (sexual interest, sexual activity and sexual enjoyment). Cronbach’s alpha coefficients range from 0.74 to 0.86 (lymphoedema 0.80, urological symptoms 0.75, gastrointestinal symptoms 0.74, body image problems 0.86 and sexual/vaginal problems 0.86) and convergent and discriminant validity has no scaling errors for the subscales.
Data analysis and reporting
Interviews were audio-recorded, transcribed verbatim, translated and checked for accuracy by the local research team to prevent loss of context. Transcripts of interviews were anonymized before they were sent to the coders. Two coders (DdH and MR) performed thematic analysis on the data in NVIVO version 12. Transcripts of interviews were examined in detail in order to identify basic patterns and recurrent themes using line-by-line coding [18, 19]. The biopsychosocial model was the framework in which key themes and subthemes were created by comparing each theme with the rest of the data to create analytical categories and then grouping categories together . Coders discussed their findings, adjusted themes, and resolved differences until consensus was reached. Themes were created for uterine STS patients and HCPs separately, but sequentially by the same two coders. Thus, coding for HCPs was informed by previous coding from the patient group. This created uniformity of themes within the biopsychosocial model for patients and HCPs to facilitate the development of a measurement strategy for HRQoL in uterine sarcoma patients. Translations of quotes selected for this manuscript were checked by a native English speaker. The COnsolidated criteria for REporting Qualitative research (COREQ) for this study are reported in Additional file 2: File 2.
Data from the questionnaire reviews (comment on topic and item relevance with regard to the period from diagnosis up to time of this study) were analysed using descriptive statistics (e.g. missing data, means, standard deviations) and prevalence ratio (number of patients who experienced each complaint, i.e. who scored 2, 3 or 4, divided by the total number of patients who completed that item, multiplied by 100). As an exploratory aim, relevance of the items in these questionnaires was analysed with cut-off values adapted from the decision rules for selection of items in phase 1 studies in the EORTC Quality of Life Group Guidelines for Developing Questionnaire modules , also described in a separate publication of the study protocol :
Mean score > 1.5
Prevalence ratio > 30%
If relevance scores for an item met both the aforementioned criteria, the item was considered relevant.
Thirteen patients with uterine STS participated in semi-structured interviews to gain insight in the HRQoL issues they face and how this impact can be measured. Additionally, 23 HCPs with experience of working with uterine STS patients commented on issues specifically relevant in this patient group. Sociodemographic and clinical information of patients and HCPs is presented in Table 1.
Interview analysis-main themes
From the thematic analyses of the patient and HCP interviews, a total of eighteen, eleven, and six subthemes were defined within the physical, mental, and social health themes, respectively. The issues from the subthemes were further divided into categories, which are presented side by side for patients and HCPs in Table 2. HCPs reported both issues specifically for uterine STS patients only and issues relevant to the sarcoma patients’ population in general (indicated in Table 2). All related quotes from the interviews are presented in Additional file 1: File 3.
Uterine tumours caused heavy periods or postmenopausal blood loss, leading to the eventual sarcoma diagnosis. HCPs reported symptoms of vaginal discharge, fistulation, or, in exceptional cases, a protruding mass from the vagina as a direct consequence of the tumour.
Patients and HCPs mentioned that uterine STS also caused gastrointestinal complaints, such as changed bowel habits like constipation or diarrhoea, “feeling bloated and uncomfortable due to the pressure on my abdomen” (Footnote 1pt 3, 61 years, undifferentiated spindle cell sarcoma) or they noticed a growing mass in the abdomen “.. meanwhile my belly was growing enormously. I even said to a colleague: ‘It seems like I am four months pregnant’.” (pt 9, 59 years, leiomyosarcoma). The large tumour impacted appetite, leading to weight loss. Treatment with radiotherapy or chemotherapy also caused gastrointestinal symptoms, such as diarrhoea, gastro-esophageal reflux, nausea and vomiting, or rectal bleeding as mentioned by a HCP. After surgery, one patient mentioned she experienced a tingling sensation in her hips when she needed to open her bowels.
Both patients and HCPs reported that after surgery urinary incontinence is common, with leakage of urine and having to rush to the toilet. Patients also had to urinate more frequently, which could be related to the tumour pushing on the bladder or to surgery. Finally, HCPs also reported patients can experience pain when urinating: “have you had pain or burning feeling when passing urine, yes a lot of them they come with this complaint” (HCP 2, age missing, medical oncologist).
Being treated for uterine STS had a significant impact on the sexual life of patients. Women described the decreased ability to reach an orgasm after removal of the uterus: “My orgasm really is much less.’ Because the uterus is a muscle. I had a big, nice, long lasting orgasm. And often. And that is gone. Just like that, gone together with the uterus.” (pt 9, 59 years, leiomyosarcoma). Sexual intercourse also was less pleasant because of less sensitivity, more pain, and vaginal dryness. “Because it's quite dry and it's sore, I tried quite a bit of lubricants but that gets sore, so that does affect my libido.” (pt 13, 56 years, endometrial stromal sarcoma).
HCPs reported that treatment can lead to infertility, which can be related to all treatment modalities: “especially pelvic surgery and radiation as well, and a very toxic chemotherapy, there is issues with fertility.” (HCP 6, 41 years, surgical oncologist). Furthermore, female patients abruptly entered menopause due to removal of the ovaries or hormonal therapy for hormone receptor positive uterine sarcomas, and experienced complaints as hot flushes, night sweats, vaginal dryness, joint pain, and insomnia. Menopausal women were advised to stop taking hormone replacement therapy (HRT), leading to more symptoms: “No, I was on HRT beforehand, and so, that was helping me with the hot flushes and everything, and then I had to stop taking it because of the cancer and everything. Then, the hot flushes came back..” (pt 12, 54 years, leiomyosarcoma).
Patients and HCPs reported neurological symptoms such as numbness or tingling in the legs and/or feet, which could have an impact on mobility such as when riding a bicycle: “Yes, I have a tingling feeling, when I am on the bicycle.” (pt 9, 59 years, leiomyosarcoma). In some cases, patients were also limited in performing activities of daily living, for example in getting dressed “I need help. I can shower myself independently, but then my feet aren’t washed. And with dressing too.” (pt 9, 59 years, leiomyosarcoma) or performing household chores. Both patients and HCPs mentioned impairments in mobility, regarding driving a car, difficulties walking long distances, or walking stairs. Patients also reported lack of physical fitness and inability to do sports or leisure activities “And on the other hand, in the past 1.5 years, I have been very much occupied with the fact that I can’t to run anymore, I can’t jump anymore. I was a gymnast. Yes, and I was always dancing. I still dance, but limited.” (pt 9, 59 years, leiomyosarcoma).
All patients experienced varying degrees of fatigue and lacking energy during and sometimes also still after treatment:”And now it is going alright, but I am just really tired.” (pt 10, 55 years, adenosarcoma). One patient attributed fatigue to her hormonal changes “The other thing is I do feel tired, exhausted because of the oestrogen effect, I'm sure.” (pt 13, 56 years, endometrial stromal sarcoma). Additionally, patients had trouble sleeping, but the causes differed, such as having to go to the bathroom frequently but now the tumour is pushing on my bladder, I'm up in the night all the time going to the loo” (pt 12, 54 years, leiomyosarcoma) or because of worrying “If I go to bed on time, at 10 PM, I don’t sleep and I am afraid of death. So I sleep badly. I go to bed when I feel tired.” (pt 9, 59 years, leiomyosarcoma).
Some patients complained of shortness of breath or respiratory symptoms that only occurred during exertion: “The most intense thing I feel is maybe on exertion the pressure on my chest.[..] So I swam one kilometer the other day. And then I do feel the pressure on my chest and what not.” (pt 11, 54 years, leiomyosarcoma).
Pain also occurred in various circumstances and locations. Women had pain caused by the tumour itself: “I've got a big lump in my stomach, and occasionally that’s a bit sore.” (pt 12, 54 years, leiomyosarcoma), but also back pain related to bone marrow stimulation during chemotherapy. Patients had postoperative pain, needed pain medication, and had to deal with its side-effects as well: “had constipation and can’t no longer manage it through home remedies as used to before.” (pt 4, 58 years, rhabdomyosarcoma).
HCPs described that extensive surgery for uterine STS could have both negative and positive consequences. Negatively, patients might need a colostomy, urostomy, or nephrostomy, or they can suffer from (abdominal wall) herniation: “hernias or incisional issues long term because of the size and extent of the incisions” (HCP 6, 41 years, surgical oncologist) or lymphedema. Positively, patients could experience a relief of symptoms, caused by the local effects of a large uterine tumour: “The quality of life is improved enormously after the surgery. Because people get really sick from that sometimes, from those large tumours. Just literally get sick from it. And after the surgery they feel fitter and better and so on.” (HCP 16, 42 years, surgical oncologist).
Other treatment-specific issues reported by patients with uterine STS included feeling ill or having flu-like symptoms, lower resistance to infections, hair and nail problems, eye and mouth problems, and skin changes during chemotherapy treatment. After radiation therapy for uterine sarcoma, women had a burning, painful skin, or blisters. Another patient had developed an ulcer near the anus.
Finally, women with metastatic tumours reported problems related to metastases or local treatment for sarcoma, such as difficulty eating and speaking, and removal of teeth because of metastasis in the jaw. Another patient mentioned being more sensitive to smell after lung surgery and weight gain as exercise was limited after treatment for a pelvic bone metastasis.
Many patients experienced the diagnosis of cancer and moreover, a rare cancer, as a shock. They did not expect a sarcoma diagnosis because of a lack of symptoms or supposed benign cause of symptoms: “And as [the baby] was born, they found what they thought was just like a little nodule in my womb, which they said is probably nothing. Everyone has these, it’s kind of like endometriosis or something similar to that, nothing to worry about. Yada yada yada. And then we went through further research on it, it actually turned out it was sarcoma. It came completely out of the blue because at no point had I any kind of symptoms and actually the surgeon even said, unfortunately this type of sarcoma is often symptomless. If we wouldn’t have found it because of this, you would probably have found it two weeks later and there would be nothing I could do.” (pt 7, 39 years, endometrial stromal sarcoma). HCPs acknowledged this phenomenon as well and also emphasized that earlier misdiagnosis can have long-term effects on patients’ mental well-being: “She has really struggled from a psychological point of view, partly because of earlier misdiagnosis, and she had that sort of protracted time to diagnosis and treatment. That’s brought with her a lot of anxiety, she’s had a change in career. She’s had a lot of psychological burden that she’s carried with her.” (HCP 21, 33 years, physiotherapist).
Patients with uterine STS described feeling distressed because of the lack of knowledge about sarcoma, either because they did not understand the disease themselves “And I think I still don’t quite understand what the difference between sarcoma and so-called normal cancer is. Also, specifically to sarcoma, because the other thing that you hear a lot from the doctors, it’s not your typical cancer, so what is typical cancer and how.." (pt 7, 39 years, endometrial stromal sarcoma) or because there is less information about this rare type of cancer available: “Because the population is so small, it’s just understanding how big are the risks if you do this or you don’t do that? Because there’s just not a lot of data, there’s not a lot of knowledge, it’s hard to understand myself, but it’s also hard to almost talk about it, because you’re not quite sure.” (pt 7, 39 years, endometrial stromal sarcoma). One patient mentioned she felt the need to have contact with fellow patients to better understand how she was doing herself: To have some sort of comparison: what’s the deal? What does that do to you? To compare a bit where you stand as well, or something. [..] somewhere you feel the need to sort of.. check”. (pt 11, 54 years, leiomyosarcoma).
Being diagnosed with uterine STS also caused uncertainty regarding treatment, related to the morbidity of surgery or effectiveness of treatment: “Yes. Well yes, yes. To the extent that it is effective, you also don’t know how long it will take before it comes back” (pt 8, 59 years, leiomyosarcoma). Furthermore, patients with uterine sarcoma didn’t know what to expect in the future: “And obviously, you know I’m only 39, I think just understanding what that means for your future life. I think that’s been the biggest blow for me and also because it’s not… It’s just so hard to digest but it’s also hard to know what questions to ask.” (pt 7, 39 years, endometrial stromal sarcoma).
Women frequently experienced fear of recurrence, tainting the enjoyment of things in life: “But every day I am afraid that I am going to start feeling something related to cancer again. So there is always dust over the beautiful things. And that is very big.” (pt 9, 59 years, leiomyosarcoma) The anxiety often culminated at the moment of the next follow-up scan: “Every time I go for a scan it is again the anxiety builds up until the diagnosis, I mean until the results come I am a bit anxious. That week is quite stressful going through the scans” (pt 13, 56 years, endometrial stromal sarcoma). HCPs indicated that this is specific to patients with uterine sarcoma, because of the initial delay in diagnosis and/or unexpected news of suffering from a malignant disease. Patients also worried about the impact of their illness on loved ones. Some even decided not to tell family or friends about the severity of their situation: “But in [country of origin] because they're far away we thought it best not to discuss and that's what I want. And I don't think it will make much difference. They would simply worry there.” (pt 13, 56 years, endometrial stromal sarcoma).
Patients also reported being worried about having sex again, however they felt hesitant to discuss this with their medical team “I have an intense fear of causing vaginal bleeding again, and am embarrassed to discuss the issue with my physician.” (pt 4, 58 years, rhabdomyosarcoma). HCPs underlined the latter issue and recognized that concerns related to sexual issues are rarely brought up by patients themselves during appointments.
HCPs mentioned that women of reproductive age experience distress because they are faced with challenging decisions about having children as there is a high risk that treatment would cause infertility: “And then there was before the radiation there was this issue with fertility if there should be an operation, I think an colorectal operation to change her ovary location or not. And she already had a child but then there was the issue if you want to have another and she had to discuss the pros and cons with her husband and her family.” (HCP 12, 40 years, psychologist). According to HCPs, some patients experienced having to undergo fertility preservation as an additional burden: “in women [fertility preservation] can delay [treatment] quite a bit. And that actually is a psychological burden, because ‘you say that I have a good prognosis, I want to have children, but I also want to be treated for this’.” (HCP 10, 56 years, radiation oncologist).
Treatment for sarcoma also had an impact on the patients’ body image: women with uterine STS reported feeling less attractive compared with before being diagnosed. HCPs recognized this issue in their patients as well and reported this has great impact on patients’ self-esteem: “I think, probably, having a hysterectomy and if there were other surgery, can affect their perception of themselves or the feeling that something is missing. So, that can also have effects on the psyche,” (HCP 18, 49 years, medical oncologist).
Patients with uterine STS reported feeling more emotional or sad since diagnosis. Furthermore, they felt constantly reminded about their (previous) illness, either because of physical impairments or the psychological impact: “for the psychological aspect I still get post traumatic. [..] Yes, probably women come with heavy periods and [as their GP]I'm sending them for operation it just gets me the flashback of what I've gone through. Especially with women who are menopausal.” (pt 13, 56 years, endometrial stromal sarcoma).
Patients with uterine STS mentioned that their illness has had massive implications in their life and the activities they did or relations they had were significantly affected. For many patients, the effects of treatment caused limitations in participating in activities outside the house: “I would maybe think twice about meeting someone of an evening if that was the day my eyes seemed to be bright-red and pouring, just because it’s not very pleasant.” (pt 6, 57 years, leiomyosarcoma). This problem was also affirmed by HCPs. Side-effects of chemotherapy and radiation therapy also hampered social activities with others “During chemotherapy and because of treatment side effects I chose to lower my engagement with others, diarrhea and nausea were the main causes.” (pt 4, 58 years, rhabdomyosarcoma). Patients also had to give up leisure activities, hobbies, or activities with their (grand) children “Swimming is not possible because of infections, this is important because this is "quality time" with my daughter.” (pt 2, age missing, leiomyosarcoma).
The diagnosis also changed relationships with friends or family, due to a lack of understanding “I've got a few close friends, but I've got one close friend who initially was really upset, and I wasn’t. I felt I was helping him more, and I was like, yes, you’ve just got to accept it.” (pt 12, 54 years, leiomyosarcoma) or how people react to hearing about their illness. In some cases, they even lost contact with friends and women with uterine sarcoma felt isolated from others.
Patients with uterine STS also had to deal with loss of independence, either regarding housing “I'm a bit worried about that, how I'm going to end up, or whether I should live with my family, or I might just save to move away. Luckily, I've got those options. I can do that financially, but I worry about whether I need to be near my family forever now, if you see what I mean.” (pt 12, 54 years, leiomyosarcoma) or mobility “I still can’t drive a car at this time. So the mobility, going somewhere, the freedom of going somewhere, the autonomy, the independence, is taken away.” (pt 9, 59 years, leiomyosarcoma).
Patients often experienced limitations in continuing their studies or their original work, and often had to interrupt or adjust their working activities: “I reduced the workload, I used to do a lot of out of hours and all, I've reduced that” (pt 13, 56 years, endometrial stromal sarcoma). They felt it gave them the opportunity to focus on their recovery and to relax more. Others were forced to stop working entirely or chose to stop working. One patient experienced financial difficulties due to medical costs: “I have a lot of financial problems due to the disease, I have far less money, only 250 euros for living.” (pt 1, 46 years, sarcoma NOS).
The majority of HRQoL issues identified from the interview data are covered by the EORTC QLQ-C30 and EN-24 (see Table 2). Issues within the physical domain are assessed by both questionnaires. Heaviness or swelling of the abdomen, gynaecological symptoms, hormonal problems, treatment-related effects, weight problems, local effects of the tumour and infertility were missing from the questionnaires. The EORTC QLQ-C30 only assesses if patients are being worried, not specifying what causes them to worry. Changes in body image are assessed by the EORTC QLQ-EN24. The other mental health issues found in the interviews are not covered by either questionnaire. Nearly all social health issues are assessed by the EORTC QLQ-C30, although not always in detail (e.g. related to relationships with others). Changes in work or study capacity and the impact of a changed life are not included.
All patients with uterine sarcoma reviewed the EORTC QLQ-C30 (Table 3) and EORTC QLQ-EN24, for topic and item relevance (Table 4). Based on the mean and prevalence scores, 3 of 5 items of the physical functioning scale, 1 item of 4 items of the emotional functioning scale, 1 of the 2 items of the symptom scale ‘pain’, the 2 items of the ‘nausea/vomiting’ scale, and 2 single items of diarrhoea and financial difficulties of the EORTC QLQ-C30 were less relevant.
In terms of the EORTC QLQ-EN24, both items of the lymphedema symptom scale, 1 of 4 items of the urological symtom scale, 2 of 5 items of the gastrointestinal symptom scale, and the single item ‘tingling or numbness in hands or feet’ were less relevant based on the mean and prevalence scores. Of note, the items of sexual/vaginal problems and sexual enjoyment scale were completed by 7 out of 13 of uterine sarcoma patients.
During the qualitative assessment of the EORTC QLQ-C30 and the EORTC QLQ-EN24, patients and HCPs reported whether some items were missing, or could be changed or deleted. Their recommendations for changes and missing issues are included in Tables 3 and 4. No suggestions were made for deletion of items.
This is the first study to investigate HRQoL issues, both from the perspective of patients and of HCPs, and how they can be measured in uterine STS patients using a mixed-method design. The most commonly reported physical health issues were related to sexual and functional problems, urological symptoms, fatigue, pain, and treatment-related adverse effects. Hormone-related issues and a variety of gastrointestinal symptoms were also found. Regarding mental health, fears (about having sex, of recurrence, or of death), a changed body-image, and dealing with a lack of knowledge of sarcoma had a strong impact on HRQoL. Social health issues were related to changes in relationships with others, limitations in undertaking activities, loss of independence, changes in work or study capacity and financial difficulties.
Physical health issues reported by uterine sarcoma patients in our study overlap with issues in other gynaecological cancers. Similar to other female cancers , women with uterine sarcoma entered menopause as a result of treatment or, in the case of hormone sensitive tumours, were prohibited from using hormone replacement therapy. This led to many hormone-related symptoms, also known as the genitourinary syndrome of menopause (GSM) . In addition to GSM, limited sexual desire because of chemotherapy-related toxicity such as nausea, fatigue, and impacted body image due to chemotherapy-induced alopecia (i.e. feeling less attractive or feminine) are known to contribute to sexual dysfunction in female cancer patients . Our study found the same issues and impact on sexual functioning. The presence of gastrointestinal and urological symptoms also matches with findings in previous studies in uterine sarcoma patients, as well as in cervical and endometrial cancer survivors [15, 23]. However, in the latter group pelvic radiation is known to contribute to symptom severity. As this treatment modality is not administered routinely for uterine STS, it is not clear if the severity is comparable as well.
The HRQoL issues in the psychosocial domain are similar between patients with uterine STS and other gynaecological cancers. Patients recalled the sarcoma diagnosis coming as a shock. A survey conducted among gynaecological sarcoma patients by the British sarcoma charity showed a similar pattern in the diagnostic trajectory, with 53% of respondents going into surgery without suspecting their problem might be cancerous . HCPs thought diagnostic delay and subsequent shock of diagnosis led to an increased fear of recurrence. No studies investigated impact of diagnostic trajectory on fear of recurrence specifically, but diagnostic delay could cause psychological distress . Patients also reported fears of having sex, a domain of sexual dysfunction in female cancer patients that has been poorly reported in literature. However, there is some evidence of psychoeducational interventions that can reduce sexual fears . Uterine STS patients struggled with the lack of knowledge about their disease. This was also found in 32% of a heterogeneous sarcoma survivor population saying they found it difficult having to explain their disease . Additionally, comparable results were found regarding the desire to have contact with fellow sarcoma patients .
A variety of cancer-generic HRQoL issues were reported as well, such as fatigue, pain, chemotherapy- and radiotherapy-related toxicities, feeling tense or anxious, and impact on work, finances, and social life. These issues have been well described in the cancer population in general and are mostly covered by the EORTC QLQ-C30 questionnaire .
For the majority of the items of the EORTC QLQ-EN24, uterine sarcoma patients gave relevance scores higher than the cut-off values. The cut-off value for relevance was lower than the example (i.e. mean > 2.0) given in the EORTC QLG module development guidelines to be more inclusive for issues in the current explorative analysis , but needed to be higher than 1.0 to indicate any degree of relevance. The module development guidelines are more focused on specific tumour sites in homogeneous and common cancers, whereas the current study aims to search for a measurement strategy in a rare and heterogeneous population using existing items from item banks or libraries . Guidelines for the use of customized item lists from the EORTC QLG portfolio are currently in development , and data-driven cut-off points have yet to be defined for this process. We feel that, despite the current small number of patients, some issues can be declared as ‘insufficiently relevant’ as low relevance scores for some items can be explained by differences in phenotype or treatment between uterine STS and carcinoma patients. Lymphedema is more common in endometrial cancer patients, as they have to undergo pelvic lymph node dissection  and are more frequently overweight . Urological and gastrointestinal symptoms are mostly related to pelvic radiation, which is not part of standard first line treatment for uterine sarcoma, but can occur particularly with locoregional relapse. Tingling/numbness of the legs and feet can be caused by treatment with docetaxel, but is given less commonly than paclitaxel/carboplatin in endometrial cancer.
This study provides insight in HRQoL issues experienced by uterine STS patients, following the HRQoL conceptual model that is used in oncological clinical trials and health care [10, 31]. Although many issues match with issues reported in other urogenital cancers, it is valuable to verify these issues in the context of sarcoma diagnosis and treatment and include them in HRQoL assessment in future research. Furthermore, some issues appearing to be specific for sarcoma were identified, such as the impact of unexpected diagnosis and lack of knowledge about the disease. With regard to measurement of HRQoL, the EORTC QLQ-C30 seems to be an adequate instrument to assess cancer-generic issues in the uterine STS population. Items that had low relevance scores (e.g. nausea/vomiting, diarrhoea) are known to be less relevant in a ‘cancer-survivor’-population . A survivor-specific module is currently in development , and may be used in sarcoma patients as well. The EORTC QLQ-EN24 is also applicable in uterine STS patients, although some items seem to be redundant based on relevance scores. On the other hand, some issues specific to the sarcoma population could be added such as menopausal symptoms, pressure or heaviness in the abdomen, or the lack of contact with fellow patients. Items about sexuality are deemed relevant, looking at both relevance scores and interview analysis, however were not completed by all patients. This phenomenon was previously seen in validation studies for the EORTC QLQ-EN24 as well [14, 33]. Given the fact that HCPs acknowledged during the interviews that sexual problems are discussed infrequently and that insufficient psychosexual support is offered, it appears to be important to include items about sexuality in HRQoL assessment in uterine STS patients.
Although this is the first study to investigate HRQoL in this patient group specifically, some limitations need to be taken into account. First, the sample size of uterine sarcoma patients is small. Furthermore, no gynaecologists were interviewed despite their involvement in some countries in follow-up care for women treated for localized uterine STS. This is caused by the fact that the larger mixed method study, in which the current data was collected, was aimed at the heterogeneous sarcoma population and HCPs working in sarcoma care . Systematic review of the literature revealed that limited data was available on HRQoL in uterine sarcoma patients, prompting us to conduct analysis on data available for this subgroup. Additional issues could have come up if more uterine sarcoma patients and gynaecologists were included. Second, several interviews were conducted during the global COVID-19 pandemic which may have influenced HRQoL of uterine sarcoma patients. However, patients were explicitly asked about their sarcoma-specific experience and we found no mention of the COVID-19 pandemic or its restrictions in the transcripts. Third, we had no access to the qualitative data on which items of the EORTC QLQ-C30 and EORTC QLQ-EN24 were originally based, so we could not distinguish if they reflect the issues found in our interviews or need to be adjusted for the uterine STS population based on the comments in our interviews. Correlations between specific issues and overall health or quality of life could be analysed using item scores instead of relevance scores that were collected in our current study. Finally, we did not assess comprehensibility (i.e. whether the items are understood by patients as intended) of the EORTC QLQ-C30 and EORTC QLQ-EN24, which is a third aspect of content validity . Comprehensibility of these questionnaires has already been assessed in their validation-studies [13, 14] and we assumed that it would be similar in the context of uterine sarcoma patients.
The aforementioned insights in specific HRQoL issues experienced by uterine sarcoma patients will help create awareness in HCPs caring for patients with uterine sarcomas, improve provision of information to patients, and facilitate personalized supportive care. Our findings also offered guidance for the development of a flexible measurement strategy for HRQoL assessment in sarcoma patients, using existing cancer-generic and location-specific questionnaires combined with tailored item lists. The next phase of this mixed-method study is currently ongoing , in which the results reported here are incorporated. HRQoL issues based on interviews will be reviewed by a larger number of sarcoma patients with the aim to determine which HRQoL issues are sufficiently relevant to be considered for sarcoma subgroups, including uterine STS. The new measurement strategy will facilitate collection of sarcoma-specific patient-reported outcome data in clinical trials and observational studies, and help determine patient groups for whom care can be personalized.
Patients with uterine STS experience a variety of issues in the physical, mental, and social domain that impact their HRQoL. Some issues were specific for the tumour location, others were related to the rare sarcoma diagnosis specifically. The majority of items in the existing EORTC QLQ-C30 and EORTC QLQ-EN24 questionnaires were relevant for HRQoL, although some additional issues were missing. For future research, a flexible measurement strategy combining cancer-generic, location- and sarcoma-specific items is recommended to assess HRQoL in uterine sarcomas.
Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due them containing information that could compromise research participant consent but are available from the corresponding author on reasonable request.
indicates patient or HCP ID, age at study participation, sarcoma histological subtype for patients or specialism for HCPs.
EORTC quality of life core questionnaire 30
EORTC QLQ-endometrial cancer module
Genitourinary syndrome of menopause
Health care professionals
Health-related quality of life
Hormone replacement therapy
Storey L, Fern LA, Martins A, Wells M, Bennister L, Gerrand C, et al. A critical review of the impact of sarcoma on psychosocial wellbeing. Sarcoma 2019;2019(9730867).
McDonough J, Eliott J, Neuhaus S, Reid J, Butow P. Health-related quality of life, psychosocial functioning, and unmet health needs in patients with sarcoma: a systematic review. Psycho Oncol. 2019;28:653–64.
Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer. 2016;26(6):1098–104.
Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348–65.
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18.
Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, et al. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG oncology/gynecologic oncology group study. J Clin Oncol. 2018;36(33):Jco1800454.
Thanopoulou E, Aleksic A, Thway K, Khabra K, Judson I. Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital. Clin Sarcoma Res. 2015;5:8.
George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014;120(5):738–43.
Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553–8.
Skalicky AM, Ghate SR, Perez JR, Rentz AM. Results of a qualitative study to develop a patient reported outcome measure for patients with 4 subtypes of soft tissue sarcoma. Sarcoma 2017;2017(6868030).
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
Greimel E, Nordin A, Lanceley A, Creutzberg CL, van de Poll-Franse LV, Radisic VB, et al. Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J Cancer. 2011;47(2):183–90.
van Eck I, den Hollander D, Desar IME, Soomers V, van de Sande MAJ, de Haan JJ, et al: Unraveling the heterogeneity of sarcoma survivors' health-related quality of life regarding primary sarcoma location: results from the SURVSARC study. Cancers (Basel) 2020;12(11).
den Hollander D, Fiore M, Martin-Broto J, Kasper B, Casado Herraez A, Kulis D, et al. Incorporating the patient voice in sarcoma research: how can we assess health-related quality of life in this heterogeneous group of patients? A study protocol. Cancers (Basel) 2021;13(1).
Morse JM, Barrett M, Mayan M, Olson K, Spiers J. Verification strategies for establishing reliability and validity in qualitative research. Int J Qual Methods. 2002;1(2):13–22.
Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–8.
Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44(3):497–506.
Drabbe C, Grünhagen DJ, Van Houdt WJ, Braam PM, Soomers V, Van der Hage JA, et al. Diagnosed with a rare cancer: experiences of adult sarcoma survivors with the healthcare system-results from the SURVSARC study. Cancers (Basel). 2021;13(4):679.
Piccinin C, Kulis D, Bottomley A, Bjordal K, Coens C, Darlington AS, et al. Development of scientific guidelines for use of the EORTC Item Library in cancer clinical trials. Value Health. 2019;22:S112–3.
Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health. 2017;20:838–55.
van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, et al. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018;16(1):114.
Stukan M, Zalewski K, Mardas M, Filarska D, Szajewski M, Kmieć A, et al. Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J Cancer Care (Engl). 2018;27(1):e12639.
Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27(5):1159–70.
OH and WvdG conceptualized the study and acquired funding. DdH, EL, SSi, SSo, MF, ID, OH and WvdG developed methodology. DdH, EL, SSi, SSo, SSa, MF, CB, ID, and WvdG contributed to patient recruitment. DdH, EL, SSi, SSo, and VB performed interviews. DdH, MR, IvE, and OH performed analysis. The original draft was prepared by DdH, OH, and WvdG. All authors reviewed and edited the manuscript. All authors read and approved the final manuscript.
Ethical approval was given by the Institutional Review Board of the Netherlands Cancer Institute (IRB18121). In the other international participating centres, this study was approved by their ethical committees according to local regulations.
Consent for publication
The authors have no conflict of interest to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
den Hollander, D., Lidington, E., Singer, S. et al. ‘I thought I had fibroids, and now I don’t’: a mixed method study on health-related quality of life in uterine sarcoma patients.
Health Qual Life Outcomes20, 65 (2022). https://doi.org/10.1186/s12955-022-01971-5